A highly immunogenic UVC inactivated Sabin based polio vaccine

Area of Science:

• Vaccinology
• Microbiology
• Biotechnology

Background:

• Current polio vaccines, oral polio vaccine (OPV) and inactivated polio vaccine (IPV), have limitations hindering global eradication.
• OPV carries risks of reversion to pathogenic forms and vaccine-derived diseases.
• Conventional IPVs involve high manufacturing costs and biosecurity risks.

Purpose of the Study:

• To develop an improved polio vaccine candidate addressing the limitations of existing vaccines.
• To create a novel inactivation method preserving vaccine immunogenicity.

Main Methods:

• Development of a novel Ultraviolet-C (UVC) radiation inactivation method.
• Incorporation of a manganese-decapeptide-phosphate (MDP) antioxidant complex from Deinococcus radiodurans.
• Production of the ultraIPV™ vaccine candidate using UVC and MDP.

Main Results:

• The ultraIPV™ candidate demonstrated complete inactivation, eliminating risks of vaccine-associated diseases.
• Production utilizes non-pathogenic strains, significantly reducing biohazard risks.
• Enhanced yield of vaccine doses per milligram of input virus, potentially lowering costs and increasing supply.

Conclusions:

• The novel UVC inactivation method with MDP produces a robust polio vaccine candidate, ultraIPV™.
• ultraIPV™ addresses safety, production, and supply challenges associated with current polio vaccines.
• This advancement supports the goal of global polio eradication.